Keryx aims for dual listing on high-growth exchanges
WESTLB and Roth Capital should complete the first simultaneous Nasdaq and Aim listing next week.
The $46m-$55m IPO of Keryx Biopharmaceuticals was due to close on Tuesday, but has been postponed and will be completed imminently, a banker close
to the deal said. The deal
...
Already a subscriber? Login
Further Reading
-
SRI / Green Bonds
UK’s green Budget ‘underwhelming’ as gaps, contradictions appear
-
IPOs
Equity market cheers London listing review
-
ABBs/Block Trades
Shareholder sells Melexis shares to increase freefloat
-
Follow-Ons/Rights Issues
EDPR sells cheap to price €1.5bn 're-IPO' amid rising bond yields inflation fears